Skip to content

Pricking blood therapy for chronic urticaria: a randomized controlled trial

Clinical evaluation study of pricking blood therapy based on Xuanfu theory in the treatment of chronic urticaria

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005233
Enrollment
Unknown
Registered
2021-08-27
Start date
2021-12-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Urticaria

Interventions

Sponsors

Hebei University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria of chronic urticaria in the EAACI/GA2LEN/EDF/WAO guidelines for the treatment of urticaria (2017) and the Chinese guidelines for the treatment of urticaria (2018); 2. Aged 18-70 years; 3. No antihistamines use within 2 weeks before enrollment and no steroids or immunosuppressive drugs within 1 month; 4. The liver and kidney functions are normal; 5. Not participating in other ongoing clinical studies; 6. Voluntary participation and signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Unconscious people who cannot express subjective symptoms of discomfort and psychiatric patients; 2. Those with Progressive malignant tumors or other serious wasting diseases, who are prone to co-infection and bleeding; 3. Patients with severe primary diseases such as cardiovascular, liver, kidney, digestion, hematopoietic system; 4. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Urticaria activity score (UAS);

Secondary

MeasureTime frame
Visual analogue scale (VAS);Dermatology Life Quality Index (DLQI);

Countries

China

Contacts

Public ContactDu Yuzhu

Hebei University of Chinese Medicine

duyuzhu6899@163.com+86 18932916899

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026